— A three-question test covering our series on scattered big B-cell lymphoma
by
Leah LawrenceContributing Writer, MedPage Today
December 26, 2023
Understanding about the biology of scattered big B-cell lymphoma (DLBCL) and the variety of treatments authorized for the illness continues to grow.
This three-question test will check one element from each post in MedPage Today‘s Clinical Challenges series on DLBCL that covered the following: usage of bispecific antibodies versus CAR T-cell treatment in the relapsed/refractory illness setting; adoption of the first-line program of polatuzumab vedotin (Polivy) with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP); and the prophylaxis and treatment of main nerve system (CNS) regression
Proper responses and descriptions appear after finishing the test.
-
Leah Lawrence is a freelance health author and editor based in Delaware.